Results 141 to 150 of about 2,111,359 (357)

A Review of Urban Biodiversity Management: Local Authority approach

, 2022
Norziana Ahli, Robiah Suratman, Nadzirah Hosen, Zainab Toyin Jagun   +3 more
openalex   +2 more sources

Interaction of HS1BP3 with cortactin modulates TKS5 localisation, cell secretion and cancer malignancy

Molecular Oncology, EarlyView.
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen, Kristiane Søreng, Chiara Veroni, Laura Trachsel‐Moncho, Nagham Asp, Robin Gaupset, Lars Gustav Lyckander, Helene Knævelsrud, Lars Eftang, Anne Simonsen   +9 more
wiley   +1 more source

Supporting and enabling health research in a local authority (SERLA): an exploratory study. [PDF]

BMC Public Health, 2022
McGee CE, Barlow-Pay M, Vassilev I, Baird J, Fenge LA, Chase D, Parkes J.   +6 more
europepmc   +1 more source

Public satisfaction in local authorities: A case study in Kedah [PDF]

, 2011
Zaherawati Zakaria, Kamaruddin Ngah, Jamaludin Mustaffa, Nazri Mohd Noordin, Mohd Zool Hilmie Mohamed Sawal, Mahazril ‘Aini Yaacob   +5 more
openalex  

Promoting a reading culture in school community: how to engage reading activities cross curricula, directors, teachers, students, parents, administrative services, local authorities, public libraries and other partners – Relating a project

, 2021
Ana Bela Martins, Alexandra Angélica Marques   +1 more
openalex   +2 more sources

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Legal Implications D of the Enactment of the Job Creation Law on the Authority of Local Governments on the Implementation of Building Approvals (PBG) For Villa Construction [PDF]

I Ketut Kasta Arya Wijaya, Ni Made Jaya Senastri, I Ketut Sukadana, Luh Putu Suryani   +3 more
openalex   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Identifying local authority need for, and uptake of, school-based physical activity promotion in England-a cluster analysis. [PDF]

J Public Health (Oxf), 2022
Venkatraman T, Honeyford K, Ram B, M F van Sluijs E, Costelloe CE, Saxena S.   +5 more
europepmc   +1 more source